At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 206 enrolled
Drug / intervention
Tonlamarsen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Monthly Subcutaneous Administration of Tonlamarsen in Participants With Uncontrolled Hypertension (KARDINAL)
In Brief
A Phase 2 clinical trial evaluating Tonlamarsen and Placebo for Hypertension. Completed, enrolled 206 participants across 39 sites.
Detailed Summary
The purpose of this study is to evaluate the blood pressure (BP)-lowering efficacy of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure (BP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2026
First PostedMar 2025
Enrollment StartApr 2025
Primary CompletionJan 2026
Study CompletionMar 2026
TodayJul 2026
First PostedMar 7, 2025
Enrollment StartApr 10, 2025
Primary CompletionJan 12, 2026
Study CompletionMar 17, 2026
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.3 years ago
Interventions
Tonlamarsendrug
Tonlamarsen will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
Placebodrug
Placebo will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study